OnKure Therapeutics, Inc. (NASDAQ:OKUR) Short Interest Update

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the target of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 33,385 shares, an increase of 135.3% from the January 29th total of 14,187 shares. Currently, 0.3% of the shares of the stock are short sold. Based on an average daily volume of 101,537 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 101,537 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the shares of the stock are short sold.

OnKure Therapeutics Stock Performance

Shares of NASDAQ:OKUR traded up $0.05 on Friday, reaching $2.71. The company’s stock had a trading volume of 143,409 shares, compared to its average volume of 101,076. The company has a 50-day simple moving average of $2.75 and a 200 day simple moving average of $2.82. OnKure Therapeutics has a 52-week low of $1.70 and a 52-week high of $5.60. The company has a market cap of $36.72 million, a P/E ratio of -0.57 and a beta of 0.46.

Institutional Investors Weigh In On OnKure Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Acorn Capital Advisors LLC lifted its stake in shares of OnKure Therapeutics by 97.2% in the 2nd quarter. Acorn Capital Advisors LLC now owns 2,839,674 shares of the company’s stock valued at $6,787,000 after purchasing an additional 1,400,000 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of OnKure Therapeutics during the 4th quarter valued at approximately $2,941,000. Rosalind Advisors Inc. purchased a new stake in OnKure Therapeutics during the 4th quarter valued at $2,118,000. Shay Capital LLC lifted its position in OnKure Therapeutics by 417.8% in the second quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock worth $1,869,000 after buying an additional 631,008 shares during the last quarter. Finally, Prosight Management LP lifted its position in OnKure Therapeutics by 204.9% in the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares during the last quarter. 90.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Wall Street Zen upgraded shares of OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $32.00.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.